Combination therapy of molecular hydrogen and hyperoxia improves survival rate and organ damage in a zymosan-induced generalized inflammation model.
Yunchuan Hong, L I Sun, Ruiqiang Sun, Hongguang Chen, Yonghao Yu, Keliang Xie · Experimental and therapeutic medicine · 2016
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, the inhalation of H₂ (2%) or hyperoxia (98%) alone improved the 14-day survival rate of ZY-challenged mice from 20 to 70 or 60%, respectively. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in mice. The inhalation of H₂ (2%) or hyperoxia (98%) alone improved the 14-day survival rate of ZY-challenged mice from 20 to 70 or 60%, respectively.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 98% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 98% source-reported H₂ gas concentration; 4 L/min total gas flow (approximately 3920 mL/min H₂ component). The inhalation of H₂ (2%) or hyperoxia (98%) alone improved the 14-day survival rate of ZY-challenged mice from 20 to 70 or 60%, respectively. The authors concluded that in conclusion, combination therapy with H₂ and hyperoxia provides enhanced therapeutic efficacy against multiple organ damage in a ZY-induced generalized inflammation model, suggesting the potential applicability of H₂ and hyperoxia in the therapy of conditions associated with inflammation-related MODS. China E‑mail: xiekeliang2009@hotmail.com *Contributed equally Abbreviations: 8 -iso-PGF2α, 8 -iso-prostaglandin F2 α; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CAT, catalase; CLP, cecal ligation and puncture; Cr, creatinine; GSH -Px, glutathione peroxidase; H₂, hydrogen; H₂O₂, hydrogen peroxide; HMGB1, high -mobility group box 1; ICU, intensive care units; MODS, multiple organ dysfunction syndrome; NS, normal saline; •OH, hydroxyl radicals; ROS, reactive oxygen species; SOD, superoxide dismutase; ZY, zymosan Key words: multiple organ dysfunction syndrome /failure, reactive oxygen species, inflammatory cytokines, hydrogen gas, hyperoxia HONG et al: COMBINATION THERAPY WITH H₂ AND O₂ IN ZYMOSAN-INDUCED ORGAN DAMAGE 2591 damage (4‑8).
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 98% source-reported H₂ gas concentration.
Limitations and Safety
Safety information: H₂ has been used medically to pre v ent decompression sickness in deep divers for safety profiles (28).
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://www.spandidos-publications.com/10.3892/etm.2016.3231/download.